Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Zila has selected Getwell Life Sciences, based in New Delhi, to distribute the company's ViziLite Plus with TBlue, an oral cancer screening product, throughout India. Financial terms of the agreement were not disclosed.
Subscribe to our email newsletter
David Bethune, chairman and CEO of Zila, said: “India is obviously a major market that represents an excellent opportunity for ViziLite Plus. Through our relationship with Getwell, we plan to aggressively introduce our product all over the country.
“We are working closely with Getwell to gain the necessary regulatory approvals required by the Indian government in order to begin selling ViziLite Plus, which we expect to take approximately three months.”
Suresh Pathak, CEO and director of Getwell Life Sciences, said: “Oral cancer is the most common cancer in India, accounting for nearly 12% of all cancers detected and 50% to 70% of cancer-related deaths. The widespread practice of chewing various forms of tobacco and betel nut and smoking tobacco are the major causes of oral cancer.”